PMID- 32810485
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
VI  - 111
DP  - 2020 Oct
TI  - Cardiovascular outcomes trials with incretin-based medications: a critical review 
      of data available on GLP-1 receptor agonists and DPP-4 inhibitors.
PG  - 154343
LID - S0026-0495(20)30207-9 [pii]
LID - 10.1016/j.metabol.2020.154343 [doi]
AB  - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 
      (DPP-4) inhibitors are so called "incretin-based therapies" (IBTs) that represent 
      innovative therapeutic approaches and are commonly used in clinical practice for 
      the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome 
      trials (CVOTs) have provided useful information that has helped to shape changes 
      in clinical practice guidelines for the management of T2DM. At the same time, the 
      mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of 
      these medications are still being explored. A summary of the main findings from 
      CVOTs performed to-date with particular emphasis on various outcomes and 
      inconsistencies observed in the trials is provided. Overall, available data is 
      favourable to the early deployment of GLP-1RAs in clinical practice, fully in 
      line with recommendations from international scientific guidelines, and based on 
      their effects on glucose metabolism parameters, body weight reduction and CV 
      outcomes. Evidence further suggest that the CV benefits of GLP-1RAs may not be a 
      class effect, with GLP-1 analogues having a greater benefit rather than 
      exendin-based agents.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Sachinidis, Alexandros
AU  - Sachinidis A
AD  - Department of Health Promotion Sciences Maternal and Infantile Care, Internal 
      Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 
      Italy; 2nd Propedeutic Department of Internal Medicine, Medical School, Aristotle 
      University of Thessaloniki, Thessaloniki, Greece.
FAU - Nikolic, Dragana
AU  - Nikolic D
AD  - Department of Health Promotion Sciences Maternal and Infantile Care, Internal 
      Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 
      Italy. Electronic address: dragana.nikolic@unipa.it.
FAU - Stoian, Anca Pantea
AU  - Stoian AP
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University 
      of Medicine and Pharmacy, Bucharest, Romania.
FAU - Papanas, Nikolaos
AU  - Papanas N
AD  - Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, 
      Democritus University of Thrace, Alexandroupolis, Greece.
FAU - Tarar, Omer
AU  - Tarar O
AD  - Division of Endocrinology, Diabetes and Metabolism, School of Medicine, 
      University of South Carolina, USA.
FAU - Rizvi, Ali A
AU  - Rizvi AA
AD  - Division of Endocrinology, Diabetes and Metabolism, School of Medicine, 
      University of South Carolina, USA; Division of Endocrinology, Metabolism, and 
      Lipids, Emory University School of Medicine, Atlanta, GA, USA.
FAU - Rizzo, Manfredi
AU  - Rizzo M
AD  - Department of Health Promotion Sciences Maternal and Infantile Care, Internal 
      Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 
      Italy; Division of Endocrinology, Diabetes and Metabolism, School of Medicine, 
      University of South Carolina, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200816
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Incretins)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/drug therapy/metabolism
MH  - Cardiovascular System/*drug effects/metabolism
MH  - Dipeptidyl Peptidase 4/*metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Incretins/*pharmacology
OTO - NOTNLM
OT  - Cardiovascular risk
OT  - DPP4- inhibitors
OT  - Glucagon-like peptide 1 receptor agonists
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest The authors have given talks, attended 
      conferences and participated in advisory boards and trials sponsored by various 
      pharmaceutical companies. Prof. APS is currently Vice President of Romanian 
      National Diabetes Committee. Prof. MR is currently Director, Clinical Medical & 
      Regulatory Department, Novo Nordisk Europe East and South. The authors declare no 
      conflict of interest, financial or otherwise.
EDAT- 2020/08/19 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/01/04 00:00 [received]
PHST- 2020/08/06 00:00 [revised]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - S0026-0495(20)30207-9 [pii]
AID - 10.1016/j.metabol.2020.154343 [doi]
PST - ppublish
SO  - Metabolism. 2020 Oct;111:154343. doi: 10.1016/j.metabol.2020.154343. Epub 2020 
      Aug 16.